Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt; Department of Chemical and Biochemical Engineering, The University of Western Ontario, London, Ontario, Canada; Department of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria 21526, Egypt.
Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt; Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
Eur J Pharm Biopharm. 2018 Jul;128:156-169. doi: 10.1016/j.ejpb.2018.04.023. Epub 2018 Apr 22.
Protein-based micelles have shown significant potential for tumor-targeted delivery of anti-cancer drugs. In this light, self-assembled nanocarriers based on GRAS (Generally recognized as safe) amphiphilic protein co-polymers were synthesized via carbodiimide coupling reaction. The new nano-platform is composed of the following key components: (i) hydrophobic zein core to encapsulate the hydrophobic drugs rapamycin (RAP) and wogonin (WOG) with high encapsulation efficiency, (ii) hydrophilic lactoferrin (Lf) corona to enhance the tumor targeting, and prolong systemic circulation of the nanocarriers, and (iii) glutaraldehyde (GLA)-crosslinking to reduce the particle size and improve micellar stability. Zein-Lf micelles showed relatively rapid release of WOG followed by slower diffusion of RAP from zein core. This sequential release may aid in efflux pump inhibition by WOG thus sensitizing tumor cells to RAP action. Interestingly, these micelles showed good hemocompatibility as well as enhanced serum stability owing to the brush-like architecture of Lf shell. Moreover, this combined nano-delivery system maximized synergistic cytotoxicity of RAP and WOG in terms of tumor inhibition in MCF-7 breast cancer cells and Ehrlich ascites tumor animal model as a result of enhanced active targeting. Collectively, GLA-crosslinked zein-Lf micelles hold great promise for combined RAP/WOG delivery to breast cancer with reduced drug dose, minimized side effects and maximized anti-tumor efficacy.
基于蛋白质的胶束在抗癌药物的肿瘤靶向递送上显示出了巨大的潜力。有鉴于此,通过碳二亚胺偶联反应合成了基于 GRAS(一般公认为安全)两亲性蛋白共聚物的自组装纳米载体。这种新的纳米平台由以下关键组成部分构成:(i)疏水性玉米醇溶蛋白核心,用于包裹疏水性药物雷帕霉素(RAP)和黄苓素(WOG),具有较高的包封效率,(ii)亲水性乳铁蛋白(Lf)冠,增强肿瘤靶向性,延长纳米载体的系统循环,以及(iii)戊二醛(GLA)交联,以减小颗粒尺寸并提高胶束稳定性。玉米醇溶蛋白-Lf 胶束表现出相对较快的 WOG 释放,随后 Rap 从玉米醇溶蛋白核心缓慢扩散。这种顺序释放可能有助于通过 WOG 抑制外排泵,从而使肿瘤细胞对 RAP 作用敏感。有趣的是,由于 Lf 壳的刷状结构,这些胶束表现出良好的血液相容性和增强的血清稳定性。此外,这种组合的纳米递药系统通过增强主动靶向,最大限度地提高了 RAP 和 WOG 在 MCF-7 乳腺癌细胞和艾氏腹水瘤动物模型中的协同细胞毒性,从而达到抑制肿瘤的效果。总的来说,GLA 交联的玉米醇溶蛋白-Lf 胶束有望用于联合 RAP/WOG 递药治疗乳腺癌,从而减少药物剂量、最小化副作用并最大限度地提高抗肿瘤疗效。